Stavros V. Konstantinides et al. JACC 2016;67:

Slides:

Advertisements

Similar presentations

AM Report Lauren Galpin, MD MA  “Thromboembolic obstruction of the major pulmonary arteries due to unresolved pulmonary embolism [with pulmonary.

Advertisements

Epidemiology and diagnosis of acute pulmonary embolism Dr Sam Z Goldhaber Associate Professor of Medicine Harvard Medical School Staff Cardiologist Brigham.

Pulmonary Thromboembolic Disease By Ahmed Mansour, MSc, PhD.

Biochemical Markers of Myocardial Infarction

Pulmonary Embolism and Infarction

Thrombophilia National Haemophilia Director

DR.Manoj Parmar M.D.. Introduction  Pulmonary embolism (PE) is an important cause of morbidity and mortality among hospitalized patients.  Although.

Pulmonary Embolism and the Role of Echocardiograms in Management

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Acute Pulmonary Embolism: With an Emphasis on an.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Management of Pulmonary Embolism: An Update J Am.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.

Venous Thromboembolism Prophylaxis for Medical Inpatients

The Evaluation of Suspected Pulmonary Embolism

D-dimer and helical CT-PA based diagnostic algorithm for PE

From: Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver DiseaseA Systematic Review.

Pulmonary Embolism in the Postanesthesia Care Unit: A Case Study

Pulmonary Thrombo-Embolism

Stephen W. Waldo et al. JACC 2008;51:

Thank you for viewing this presentation.

Volume 150, Issue 3, Pages (September 2016)

Identifying and Managing Dyspnea Associated With CTEPH

Victor F. Tapson, MD, David M. Platt, MD, Fang Xia, PhD, Simon A

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

Clyde W. Yancy et al. JACC 2017;70:

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Catheter-directed interventions for acute pulmonary embolism

Dean J. Kereiakes et al. JACC 2017;70:

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

Editorial Heart Failure Clinics

Catheter-directed interventions for acute pulmonary embolism

Johannes Steiner et al. JACC 2017;70:

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

Johannes Steiner et al. JACC 2017;70:

Cohort identification and exclusion.

Robert C. Neely, MD, John G. Byrne, MD, Igor Gosev, MD, Lawrence H

Venous Thromboembolism (VTE)

Outpatient Pulmonary Embolism Management: If You Walk Into the Emergency Department With a Pulmonary Embolism, Maybe You Should Also Walk Out Tyler W.

Familial Chronic Thromboembolic Pulmonary Hypertension

Gregory Piazza et al. JCIN 2015;8:

Wayne L. Miller et al. JCHF 2013;1:

M. Rizwan Afzal et al. JACEP 2017;3:

Matthew Oster et al. JACC 2019;73:

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Nicolaj C. Hansson et al. JACC 2016;68:

Ioannis Smyrnias et al. JACC 2019;73:

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Biochemical Markers of Myocardial Infarction

Algorithm for the outpatient management of pulmonary embolism (PE)

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Svend A. Mortensen et al. JCHF 2014;2:

Stavros V. Konstantinides et al. JACC 2017;69:

Rick A. Nishimura et al. JACC 2014;63:e57-e185

Leslee J. Shaw et al. JIMG 2010;3:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Gregory Piazza et al. JCIN 2015;8:

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Example scans for a typical patient with operable chronic thromboembolic pulmonary hypertension. a) Perfusion (Q′) and b) ventilation (V′) lung scans.

Hisa Shimojima et al. JACEP 2018;4:

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

European Society of Cardiology guidelines for the diagnosis of a) clinically suspected high-risk pulmonary embolism (PE) and b) clinically suspected non-high-risk.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Relationship between pulmonary vascular obstruction (PVO) and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension (CTEPH) and.

Nephrotic syndrome is a prothrombotic state of variable magnitude.

Presentation transcript:

Stavros V. Konstantinides et al. JACC 2016;67:976-990 PE: Risk-Adjusted Management in the Acute Phase and Over the Long Term *Biochemical markers include markers of myocardial injury (troponins, heart-type fatty acid-binding protein) and markers of heart failure (BNP or N-terminal-proBNP). †Only antiphospholipid syndrome and high-risk inherited thrombophilia (i.e., homozygosity for factor V Leiden, homozygosity for prothrombin G20210A mutation, double heterozygosity, antithrombin deficiency) are considered. Nevertheless, routine thrombophilia testing is not indicated in PE patients. BNP = B-type natriuretic peptide; CT = computed tomography; CTEPH = chronic thromboembolic pulmonary hypertension; CTPA = computed tomographic pulmonary angiogram; CUS = compression ultrasound; Echo = echocardiography; N-terminal-proBNP = N-terminal pro–B-type natriuretic peptide; PE = pulmonary embolism; PESI = pulmonary embolism severity index; RV = right ventricular; sPESI = simplified pulmonary embolism severity index; V/Q scan = ventilation/perfusion lung scan; VTE = venous thromboembolism. Stavros V. Konstantinides et al. JACC 2016;67:976-990 American College of Cardiology Foundation